These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6211659)

  • 1. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
    Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferoxamine improves left ventricular function in beta-thalassemia.
    Grisaru D; Goldfarb AW; Gotsman MS; Rachmilewitz EA; Hasin Y
    Arch Intern Med; 1986 Dec; 146(12):2344-9. PubMed ID: 3778067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac status in well-treated patients with thalassemia major.
    Aessopos A; Farmakis D; Hatziliami A; Fragodimitri C; Karabatsos F; Joussef J; Mitilineou E; Diamanti-Kandaraki E; Meletis J; Karagiorga M
    Eur J Haematol; 2004 Nov; 73(5):359-66. PubMed ID: 15458515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 7. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac study by dobutamine stress echocardiography in thalassemic patients.
    Mariotti E; Agostini A; Angelucci E; Cesaroni P; Lucarelli G; Sgarbi E
    Bone Marrow Transplant; 1993; 12 Suppl 1():14-5. PubMed ID: 8374553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-thalassemia and pulmonary function.
    Piatti G; Allegra L; Ambrosetti U; Cappellini MD; Turati F; Fiorelli G
    Haematologica; 1999 Sep; 84(9):804-8. PubMed ID: 10477453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 14. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thalassemic cardiopathy: serial echocardiographic evaluation].
    Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C
    G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac dysfunction in children with thalassemia major].
    Angelika L; Graf N; Hoffmann W
    Klin Padiatr; 1988; 200(2):102-7. PubMed ID: 3386182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.